ark health semaglutide Wegovy May Help Treat Serious Liver Disease, Study Finds ark health semaglutide Ark Health

2001;25(5 Suppl):S1028

While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved

Clinical studies show that 25 to 40 percent of weight lost on GLP-1 medications like Ozempic and Wegovy can come from lean muscle mass rather than fat

Protocols should be individualized and supervised by a qualified provider

BMJ 1999